Credit Suisse Starts Coverage of Genomic Health, Myriad Genetics, Sequenom | GenomeWeb

NEW YORK (GenomeWeb News) – Credit Suisse on Monday initiated coverage of Genomic Health with an Outperform rating, Myriad Genetics with a Neutral rating, and Sequenom with an Underperform rating.

Analyst Vamil Divan initiated coverage of Genomic Health with a $43 price target and in a research note highlighted the firm's portfolio of Oncotype tests. He called Oncotype Dx Breast "a best-in-class asset that is likely to gain traction in other forms of breast cancer," and added that Oncotype Dx Colon is gaining positive reaction, driving uptake of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.